HIF1A and endometrial cancer: In conclusion, due to our findings and those of the aforementioned studies, further studies involving xenograft models of ovarian and endometrial cancers are warranted to evaluate in vivo efficacy of TM and to investigate the interplay between complex IV and HIF-1α following TM therapy.